ProShare Advisors LLC Boosts Holdings in Edwards Lifesciences Corporation $EW

ProShare Advisors LLC increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 112,537 shares of the medical research company’s stock after buying an additional 8,266 shares during the period. ProShare Advisors LLC’s holdings in Edwards Lifesciences were worth $9,594,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in EW. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter worth about $25,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $28,000. Hantz Financial Services Inc. increased its holdings in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares during the last quarter. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $29,000. Finally, Rakuten Securities Inc. increased its stake in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 106,684 shares of company stock valued at $8,811,739. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. BTIG Research lifted their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $83.24 on Friday. The company has a 50 day moving average of $81.41 and a 200 day moving average of $82.87. The stock has a market cap of $47.93 billion, a P/E ratio of 44.27, a P/E/G ratio of 2.08 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.